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Abstract 
 
Objectives:  We sought to evaluate the incidence, risk factors, in-hospital and long term 
outcomes and predictors of mortality of coronary artery perforations (CAP) in the contemporary 
percutaneous coronary intervention (PCI) era. 
Background: CAP is a rare but serious complication of PCI associated with increased risk of 
morbidity and mortality.  
Methods: We included 181,590 procedures performed across 47 hospitals in Michigan from 
1/1/2010-12/31/2015. Endpoints evaluated included the incidence of CAP and its association 
with in-hospital outcomes. Logistic regression analysis was utilized to determine independent 
risk factors for CAP and to examine whether the effect of CAP on mortality varied by gender.  
Results: CAP occurred in 625 (0.34%) of patients. Independent predictors for CAP included 
older age, peripheral arterial disease, presence of left ventricular dysfunction or cardiomyopathy, 
lower body mass index, pre-PCI insertion of a mechanical ventricular support device, treatment 
of complex lesions (Type C), and treatment of chronic total occlusions, the latter of which was 
the strongest predictor of perforation (adjusted odds ratio 7.01, p < 0.001). After adjusting for 
baseline risk, the incidence of adverse outcomes remained substantially greater in patients with a 
perforation, with an adjusted odds ratio estimate of 5.00 for mortality (95% CI 3.42-7.31), 3.25 
for acute kidney injury (95% CI 2.30-4.58), and 5.26 for transfusion (95% CI 4.03-6.87) (all p < 
0.001). Perforation was associated with a higher mortality in women than men (interaction p-
value = 0.01).  
Conclusions: CAP is a rare complication but is associated with high morbidity and mortality 
especially in women. Further investigation is warranted to determine why women fare worse 
after CAP. 
Key words: Coronary Aneurysm/Dissection/Perforation, Gender, Outcomes/Studies, Health Care 
Outcomes 
 
Page 2 of 70
Catheterization and Cardiovascular Interventions
Catheterization and Cardiovascular Interventions
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
3 
 
Abbreviations: 
1. CAP: Coronary artery perforations 
2. PCI: percutaneous coronary interventions 
3. CABG: coronary artery bypass grafting 
4. CTO: Chronic total occlusion 
5. BMC2: Blue Cross Blue Shield of Michigan Cardiovascular Consortium  
6. MVC: Michigan Value Collaborative 
7. BCBSM: Blue Cross Blue Shield of Michigan 
8. CI-AKI: Contrast-induced acute kidney injury  
9. IABP: intra-aortic balloon pump  
10. STEMI: ST-segment elevation myocardial infarction 
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Introduction 
The incidence of coronary artery perforation (CAP) during percutaneous coronary 
interventions (PCI) is estimated at 0.1% to 0.84%.
1
 Although rare, CAP is associated with an 
increased risk of adverse outcomes including tamponade, myocardial infarction, need for 
emergency coronary artery bypass grafting (CABG), and death.
2-4
 The majority of studies thus 
far have included a modest number of patients and it is unclear which pre-procedural patient 
factors are associated independently with an increased risk of CAP as well as which factors 
increase the risk of adverse outcomes after CAP. In addition, given improvement of equipment 
and therapies, advancing age of the population and changing guidelines, PCI utilization in certain 
higher risk subgroups, including the elderly or those with chronic total occlusions (CTO), has 
been increasing.
5-8 
 This study represents a large cohort of patients developing CAP after PCI and 
provides an updated analysis of the incidence, risk factors, and inpatient and long term outcomes 
associated with CAP in contemporary practice. 
Methods 
We included data from patients undergoing PCI at 47 hospitals participating in the Blue 
Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The details of the BMC2 
registry and its data collection and auditing process have been described previously.
9
 Briefly, 
procedural data on all patients undergoing PCI at participating hospitals are collected using 
standardized data collection forms. Baseline data include clinical, demographic, procedural, and 
angiographic characteristics as well as medications used before, during, and after the procedure, 
and in-hospital outcomes. All data elements have been prospectively defined, and the protocol is 
approved by local institutional review boards at each hospital. In addition to a random audit of 
2% of all cases, medical records of all patients undergoing multiple procedures or coronary 
artery bypass grafting and of patients who died in the hospital are reviewed routinely to ensure 
data accuracy.  
 The study population for this analysis included all consecutive patients who underwent 
PCI between January 2010 and December 2015.  If a patient underwent more than one PCI 
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procedure during a hospital stay, only procedural data reflecting the earliest procedure is 
included in this analysis. For a subset of Medicare beneficiaries in the dataset, 90-day 
readmission and long term survival data were available through indirect matching on admission, 
discharge and procedure dates for the index hospitalization, patient gender and date of birth, and 
hospital and operator NPI numbers with Medicare data for PCI episodes in collaboration with the 
Michigan Value Collaborative (MVC).
10, 11
  
Study endpoints 
Inpatient mortality was defined as mortality from any cause during the initial 
hospitalization following PCI. Contrast-induced acute kidney injury (CI-AKI) was defined as an 
increase in pre-procedural to post-procedural serum creatinine ≥ 0.5 mg/dl, since this definition 
has been strongly associated with inpatient mortality and new requirement for dialysis.
12
 Pre-
procedural serum creatinine values were measured within 30 days prior to PCI, with the value 
closest to time of PCI chosen as the baseline value. Peak post-procedural serum creatinine was 
defined as the highest value after PCI and prior to the next procedure or discharge. 
Statistical analysis 
Univariate comparisons were performed using student T-tests for continuous measures, 
and Fisher exact tests for dichotomous measures.  The Cochrane-Armitage trend test was used to 
assess whether the rate of CAP and the rate of treatment of CTO lesions changed over time.  
Multivariate logistic regression with stepwise variable selection using Akaike Information 
Criteria was utilized to identify pre-procedural clinical and demographic patient characteristics 
associated with the development of CAP.  Patient characteristics included as candidate predictors 
were chosen based on both significant univariate differences as well as associations with CAP 
observed in previous studies.
1-3
 
Pre-procedural patient risk of in-hospital outcomes including mortality, transfusion, and 
CI-AKI were estimated using the current BMC2 random Forest risk models from baseline patient 
clinical and demographic characteristics. The models are implemented for patient pre-procedural 
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risk prediction, and model inputs are described at the SCAI/BMC2 PCI online risk prediction 
tool available at both the BMC2 https://bmc2.org/calculators/multi and SCAI  
http://www.scai.org/PCIRiskAssessmentTools/default.aspx websites.
13-16
  Risk adjusted 
mortality, transfusion, and CI-AKI rates were estimated for sub-groups by the overall 
collaborative outcome incidence multiplied by the ratio of observed to expected outcome rates 
for the subgroup (overall rate * O/E ratio for subgroup).   
The association of CAP with adverse outcomes of inpatient mortality, need for 
transfusion and development of CI-AKI was assessed using multivariate logistic regression 
models adjusting for baseline patient risk.  To assess whether the effect of CAP on outcomes 
potentially varied by gender, likelihood ratio tests were utilized to determine whether inclusion 
of a gender by CAP interaction term significantly improved model fit. 
In the subset of Medicare patients for which long term survival data was available, 
propensity score matching was employed to account for baseline patient clinical and 
demographic variables that could confound the analysis of the impact of CAP on post-discharge 
survival. Logistic regression was utilized to construct the propensity score, and each CAP patient 
was matched to 10 similar non-CAP cases without replacement using a greedy algorithm. 
Variables included in the propensity score model and comparison of the cohorts are included in 
Supplementary Table 1 and 2. Kaplan-Meier incidence curves were used to visualize post 
discharge survival by group, and Cox proportional hazard regression was utilized to assess 
differences in survival between groups.  
Results 
 
Baseline demographics and clinical characteristics  
 
Between January 2010 and December 2015, 181,590 patients underwent PCI in the state 
of Michigan and were included in this analysis.  Of these patients, 625 (0.34%) suffered CAP 
during the PCI procedure, and 41 (6.56%) patients with perforation died prior to discharge.  The 
rate of perforation overall was relatively stable over the 6 years included in the analysis 
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(Supplementary Figure 1A).  The proportion of PCI cases where a CTO lesion was treated 
increased in statistically significant fashion over this same 6-year period, from 1.6% to 2.8% of 
all cases (Cochran Armitage trend test p value < 0.001), while the incidence of perforation 
among the subgroup of CTO cases did not demonstrate a statistically significant trend (Cochrane 
Armitage trend test p-value=0.06) (Supplementary Figure 1B-C).  
Baseline clinical, demographic and procedural characteristics for patients with and 
without perforation are provided in Table 1.  Patients with CAP were older, more likely to be 
female, have peripheral arterial disease or heart failure, require intra-aortic balloon pump (IABP) 
or other mechanical ventricular support prior to PCI, and to be in cardiogenic shock at the start of 
the procedure compared to those without CAP.  Conversely, patients with perforations were less 
likely to have diabetes.   
 Of the 625 patients who developed CAP, 22 (3.52%) underwent post-procedural 
CABG, of which 2 (9.90%) died prior to discharge.  
Association of CAP with intracoronary devices and coronary lesion variables 
Among the 625 cases of CAP, 524 (83.8%) involved only one treated vessel and these 
cases were utilized to examine the association of CAP with specific devices or coronary lesion 
variables (Table 2). Lesion length was significantly longer in vessels that developed CAP (29.24 
± 13.46 mm) compared to those without CAP (23.74 ± 13.46 mm) (p-value<0.001). The use of 
atherectomy and laser were each associated with significantly higher rates of CAP with odds 
ratio of 3.05 and 8.88, respectively (both p<0.001). When analyzing the treatment of specific 
coronary lesion variables, CAP occurred in 1.91% of patients with a treated CTO lesion 
compared to only 0.3% of patients without CTO, and a CTO PCI was the strongest univariate 
predictor of increased risk of CAP (odds ratio 6.51, Fisher Exact test p-value < 0.001). 
Predictors of CAP 
Multivariate stepwise logistic regression identified older age, peripheral arterial disease, 
presence of left ventricular dysfunction or cardiomyopathy, treatment of high complexity (type 
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C) lesions, treatment of CTO, and use of a mechanical ventricular support prior to PCI as 
predictors of CAP (Table 3). Treatment of CTO remained associated with the greatest estimated 
risk of CAP after adjusting for other covariates, with patients treated for CTO having a seven-
fold greater odds of developing CAP, odds ratio 7.01 (95% CI 5.48 – 8.98; p – value < 0.001). 
Greater height, higher body mass index and presence of diabetes were associated with a lower 
risk for the development of CAP.  
In-hospital outcomes 
Mean baseline risk estimates and outcomes of patients with and without perforations are 
provided in Supplementary Table 3.  Mean predicted risks were significantly higher in patients 
with perforation, reflecting a greater burden of comorbidites in these patients.  After adjusting for 
baseline predicted risk in a logistic regression model, patients with perforations remained at a 
substantially higher risk of adverse outcomes, with an adjusted odds ratio estimate of 5.00 (95% 
CI 3.42 – 7.31) for mortality, 3.25 (95% CI 2.30 – 4.58) for CI-AKI, and 5.26 (95% CI 4.03 – 
6.87) for transfusion (all p < 0.001). 
Predictors of in-hospital mortality 
Table 4 provides a comparison of baseline and procedural patient characteristics of 
patients with CAP who died during the hospitalization and those discharged alive.  Among the 
41 patients that died, multiple pre-procedural patient characteristics, clinical presentations, 
procedural outcomes and complications occurred more frequently including: older age, female 
gender, ST-segment elevation myocardial infarction (STEMI) presentation, recent heart failure, 
cardiogenic shock or cardiac arrest, and pre-PCI insertion of IABP or other mechanical 
ventricular support. Of the 41 perforation patients who died, 29 (70.7%) were female, compared 
to only 40.1% of those discharged alive (p <0.001).   Thirteen of the 41 perforation deaths 
(31.7%) occurred in the catheterization lab, and 20 deaths occurred on the same calendar date as 
the index PCI procedure (48.8%). 
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Figure 1 (a, b and c) provides risk adjusted mortality, CI-AKI, and transfusion rates for 
subgroups defined by gender and perforation.  The effect of CAP on mortality was significantly 
greater in women compared to men when assessed by multivariate logistic regression model 
(gender by perforation interaction p-value = 0.01).  No significant CAP by gender interaction 
was observed for the CI-AKI (p = 0.32) or transfusion (p = 0.50). 
Subsequent analysis stratified by gender demonstrated a statistically significant increase 
in mortality with CAP in both men with adjusted OR=2.70 (95% CI: 1.37 - 5.30; p-value = 
0.004) and women with an OR= 7.32 (95% CI: 4.60 – 11.65; p<0.001).   By contrast, no 
significant weight by CAP interaction was observed in the mortality model (p = 0.80), indicating 
no significant evidence that the relationship between CAP and mortality varied across the 
spectrum of patient weights  
Of the 625 cases of CAP, covered stents were successfully deployed in 70 (11.2%). Of 
the 70 CAP cases where covered stents were used, 12 (17.1%) patients died versus 29 deaths 
(5.23%) among 555 patients where covered stents were not utilized. After adjusting for predicted 
risk of death in logistic regression, the odds ratios for inpatient mortality for cases of CAP 
treated with covered stents vs. no covered stent was 4.46 (p < 0.001) likely related to the fact that 
covered stent use is reserved for perforations that are more likely to be hemodynamically 
significant. 
Long term outcomes 
Using propensity score matching, 1,030 Medicare patients without CAP having similar 
baseline clinical and demographic characteristics to the 103 available Medicare patients with 
CAP (Supplementary Tables 1 and 2) were selected. Median post-discharge follow-up in this 
cohort was 23 months for both groups, with 34 (33.0%) deaths observed among CAP patients, 
and 205 (19.9%) deaths among non-CAP patients during follow up. Kaplan-Meier survival 
curves with confidence band shading are provided in Figure 2. In Cox proportional hazards 
regression, CAP was associated with significantly greater mortality (HR = 1.63, p = .008). In 
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contrast to in-hospital mortality, no significant gender by CAP interaction was observed in Cox 
regression (p = 0.430), and women and men with CAP had comparable estimated mortality at 2 
years (men 31.1% (95% CI 14.4% - 44.6%), women 23.6% (95% CI 10.2% - 35.0%)). No 
significant difference was observed for 90-day readmission (30.1% for CAP, 23.8% no CAP, p = 
0.185) 
Discussion 
This study includes one of the largest patient cohorts describing the risk of CAP during 
PCI in contemporary practice. The incidence of CAP in our population was 0.34%, confirming 
that CAP remains an uncommon event. However, the high in-hospital mortality rate of 6.56% 
confirms the associated high mortality and highlights the need for further investigation into 
understanding risk factors, outcomes and potential therapies for this serious complication.  
Small retrospective studies have identified various patient and angiographic 
characteristics as potential risk factors for CAP including older age, female gender, presence of 
chronic kidney disease, hypertension, and previous PCI or CABG as well as angiographic 
characteristics such as type C lesions, chronic total occlusions, calcified lesions, and culprit 
lesions in the right coronary artery.
1-4
 In addition, certain procedural characteristics including a 
higher balloon to artery ratio and the use of atheroablative devices were shown in these limited 
studies to increase the risk of this serious event.
1, 3, 4
 
Our study adds to the existing literature by identifying more than 600 patients with CAP. 
Some factors that have been suggested to be associated with CAP were not found to be 
independently associated with CAP in this large study, including hypertension, chronic kidney 
disease and prior coronary artery bypass grafting.
3, 4
 However, consistent with prior studies, our 
analysis identified several patient and procedural characteristics as independent risk factors for 
CAP, including older age and treatment of chronic total occlusions.
2-4
 In fact, treatment of CTO 
was the strongest risk factor for CAP development, which is an important consideration as 
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recently there has been an increasing interest in treatment of these higher risk lesions as 
techniques and technology have improved.  
Consistent with prior work, we found CAP to be associated with an increased risk of in-
hospital mortality.
1, 2
 However, we also identified that CAP was associated with increased risk of 
long term mortality and with other adverse in-hospital outcomes, including development of CI-
AKI and the need for transfusion. Possible mechanisms to explain the increased risk of CI-AKI 
and need for transfusion include hemodynamic compromise related to development of 
complications of tamponade or myocardial infarction as well as need for additional procedures or 
surgical repair.   
Our study also demonstrated that the effect of CAP on mortality may vary by gender with 
our results indicating that perforation is significantly more deleterious in women than men.  The 
etiology of the increased risk of death in women with CAP is unknown but potentially relates to 
anatomical or hormonal differences between sexes. One hypothesis relates to a presumed smaller 
vessel diameter or differences in vessel wall thickness size in women that could increase the risk 
of development of CAP and/or higher grades of CAP.
17
 The influence of estrogen on coagulation 
factors and inflammatory markers has been proposed as a mechanism to explain the increased 
susceptibility for vascular injury. Our study did not examine the influence of smaller vessel size 
on the development of CAP, since the BMC2 database does not include information on vessel 
diameter.  
The manner in which CAP is treated is dependent on the severity of the CAP, often 
graded by Ellis type classification, and whether certain complications associated with CAP, such 
as tamponade, are present.
18
  Potential therapies include the use of prolonged balloon occlusion, 
deployment of covered stents, thrombin or gelfoam embolization, coils or CABG. We found that 
covered stents were utilized in the minority of patients with CAP, however these patients 
experienced higher rates of inpatient mortality. We hypothesize that this is related to the use of 
these therapies in more severe cases of CAP and that the worse outcomes in these patients are 
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related to this underlying higher grade perforation than the use of the covered stent itself. 
However, there is also evidence that covered stents are at higher risk for restenosis and 
thrombosis.
19
 We do not have data on the exact reason why these patients died and further 
investigation into optimal treatment of CAP is needed. 
There are several limitations to our study. First, our study was a retrospective analysis 
utilizing data from a large database which does not include details on the severity of CAP (such 
as Ellis type classification) or vessel size, which would be important to examine when attempting 
to identify the etiology of the potentially worse prognosis of CAP in women than men. In 
addition, various outcomes that may develop after CAP, including tamponade, need for 
emergency surgery or subsequent development of MI, could not be evaluated in our population 
based on database restrictions. Evaluating incidence and efficacy of various treatments for CAP 
was limited to assessing the use of covered stents in our population with CAP.  
In conclusion, CAP remains an uncommon but serious complication of PCI, associated 
with an increased incidence of inpatient mortality, CI-AKI and need for transfusion as well as 
long term mortality. Treatment of CTO lesions was the strongest independent predictor of CAP. 
Coronary artery perforations were more harmful in women than men in our study. Further 
investigation into the etiology of the poorer prognosis of CAP in women as well as efficacy of 
various therapies to treat CAP is needed. 
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1C. Risk adjusted CI-AKI associated with coronary perforation in men and women   
Figure 2: Long term mortality of propensity matched patients with and without coronary artery 
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Table 1: Characteristics of patients with and without coronary artery perforation 
 
Characteristic Coronary Perforation – no. (%) p-value 
 No 
N = 180,965 
Yes 
N = 625 
 
Demographic   
Age (years) ± SD 65.08 ± 12.02 67.35 ± 12.04 p < 0.001 
Female gender 60,349 (33.3%) 263 (42.1%) p < 0.001 
Current or recent smoker 52,677 (29.1%) 177 (28.4%) p = 0.696 
Height (cm) 171.15 ± 10.59 168.95 ± 10.86 p < 0.001 
Weight (kg) 89.70 ± 21.43 84.21 ± 19.84 p < 0.001 
Historical    
Hypertension 154,589 (85.5%) 553 (88.8%) p = 0.019 
Dyslipidemia 148,315 (82.0%) 516 (82.7%) p = 0.668 
Diabetes Mellitus 69,556 (38.4%) 221 (35.4%) p = 0.113 
Peripheral Arterial Disease 29,069 (16.1%) 126 (20.2%) p = 0.005 
Prior MI 63,507 (35.1%) 244 (39.0%) p = 0.039 
Prior PCI 82,465 (45.6%) 294 (47.0%) p = 0.464 
Prior CABG 33,415 (18.5%) 136 (21.8%) p = 0.034 
Cardiomyopathy or Left Ventricular 
Systolic Dysfunction 
19,177 (10.6%) 91 (14.6%) p = 0.001 
Procedural    
PCI Status: Elective 66,218 (36.6%) 237 (38.0%) p = 0.478 
PCI Status: Urgent 83,790 (46.3%) 287 (46.0%) p = 0.868 
PCI Status: Emergency 30,498 (16.9%) 96 (15.4%) p = 0.325 
PCI Status: Salvage 364 (0.2%) 4 (0.6%) p = 0.015 
Arterial Access Site: Radial 37,473 (20.7%) 123 (19.7%) p = 0.538 
Pre-PCI insertion of IABP or other 
mechanical ventricular support device 
2,467 (1.4%) 25 (4.0%) p < 0.001 
Pre-PCI Left Ventricular Ejection 
Fraction ± SD 
51.90 ± 12.84 49.89 ± 14.42 p = 0.003 
Cardiogenic Shock at Start of PCI 3,765 (2.1%) 24 (3.8%) p = 0.002 
 
SD: standard deviation, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass 
grafting, IABP: intraaortic balloon pump 
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Table 2: Perforations by device type and type of coronary lesion  
 
 
Percent of cases 
where device 
was used or 
lesion variable 
present 
Perforation rate 
in cases with 
device or lesion 
variable 
Perforation rate 
in cases without 
device or lesion 
variable 
Odds Ratio 
P-value      
(Fisher exact 
test) 
Intracoronary device type      
Thrombectomy 5.67% 0.31% 0.33% 0.940 0.850 
Cutting Balloon 4.92% 0.42% 0.32% 1.301 0.155 
Atherectomy 1.03% 0.98% 0.32% 3.051 < 0.001 
Bare Metal Stent 17.69% 0.32% 0.33% 0.952 0.731 
Drug Eluting Stent 72.13% 0.26% 0.50% 0.524 < 0.001 
Extraction Catheter 3.51% 0.18% 0.33% 0.535 0.043 
Embolic Protection 2.10% 0.42% 0.33% 1.281 0.357 
Laser 0.13% 2.82% 0.33% 8.876 < 0.001 
Type of coronary lesion      
Chronic Total Occlusion 1.91% 1.91% 0.30% 6.514 < 0.001 
Type C lesion 56.62% 0.36% 0.29% 1.242 0.017 
Thrombus Present 15.91% 0.26% 0.34% 0.761 .036 
Bifurcation Lesion 5.67% 0.31% 0.33% 0.940 0.850 
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Table 3: Independent adjusted risk factors for the development of coronary artery perforations 
 
 
 Odds Ratio P-value 95% Confidence Interval 
Age (per 5 year increase) 1.05 0.005 1.015-1.089 
Height (per 5 cm increase) 0.91 < 0.001 0.872-0.941 
BMI (per 1 unit increase) 0.98 0.001 0.965-0.991 
PAD 1.21 0.064 0.989-1.483 
Diabetes 0.86 0.090 0.723-1.024 
Cardiomyopathy or LV 
dysfunction 
1.30 0.026 1.032-1.633 
IABP or MV support device 
implanted prior to PCI 
2.04 0.002 1.302-3.207 
Pre-PCI creatinine 0.90 0.061 0.803-1.005 
Type C/high complexity lesion 1.15 0.100 0.973-1.364 
CTO lesion 7.01 < 0.001 5.478-8.980 
Cardiogenic shock at start of PCI 1.41 0.138 0.896-2.211 
 
BMI: body mass index, PAD: peripheral arterial disease, LV: left ventricle, MV: mechanical 
ventricular, CTO: chronic total occlusions 
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Table 4: Characteristics of patients with coronary artery perforations who were discharged alive 
versus deceased 
 
Characteristic 
Discharged alive 
N = 584 
In-hospital death 
N = 41 
p-value 
Absolute 
Standard 
Difference 
Demographic     
Age ± SD 66.98 ± 11.94 72.66 ± 12.28 p = 0.006 46.87 
Female Gender 234 (40.1%) 29 (70.7%) p < 0.001 64.85 
Current or recent smoker 162 (27.8%) 15 (36.6%) p = 0.230 18.81 
Historical     
Hypertension 518 (89.0%) 35 (85.4%) p = 0.476 10.90 
Dyslipidemia 487 (83.5%) 29 (70.7%) p = 0.036 30.84 
Diabetes Mellitus 207 (35.4%) 14 (34.1%) p = 0.867 2.73 
Prior MI 226 (38.7%) 18 (43.9%) p = 0.509 10.58 
Prior PCI 279 (47.8%) 15 (36.6%) p = 0.165 22.80 
Prior CABG 134 (22.9%) 2 (4.9%) p = 0.007 54.08 
CAD Presentation     
STEMI or equivalent 77 (13.2%) 13 (31.7%) p = 0.001 45.53 
Heart failure within two weeks 87 (14.9%) 14 (34.1%) p = 0.001 45.91 
Cardiogenic shock within 24 hours 10 (1.7%) 8 (19.5%) p < 0.001 60.37 
Cardiac arrest within 24 hours 10 (1.7%) 4 (9.8%) p < 0.001 35.11 
Pre-PCI insertion of IABP or other 
mechanical ventricular support device 
16 (2.7%) 9 (22.0%) p < 0.001 61.04 
PCI Status: Elective 231 (39.6%) 6 (14.6%) p = 0.001 58.56 
PCI Status: Urgent 267 (45.8%) 20 (48.8%) p = 0.711 5.98 
PCI Status: Emergency 85 (14.6%) 11 (26.8%) p = 0.036 30.58 
PCI Status: Salvage 0 (0.0%) 4 (9.8%) p < 0.001 46.50 
Post procedural outcomes     
Cardiogenic Shock 58 (9.9%) 30 (73.2%) p < 0.001 167.30 
Heart Failure 36 (6.2%) 8 (19.5%) p = 0.001 40.72 
 
SD: Standard deviation, CAD: coronary artery disease, MI: myocardial infarction, PCI: percutaneous coronary intervention, 
CABG: coronary artery bypass grafting, STEMI: ST-segment elevation myocardial infarction, IABP: intra-aortic balloon pump, 
CK-MB: creatinine kinase, CVA: cerebral vascular accident 
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Risk adjusted mortality, transfusion and contrast-induced acute kidney injury (CI-AKI) rates for subgroups 
defined by gender and perforation    
1A. Risk adjusted mortality associated with coronary perforation in men and women  
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Risk adjusted mortality, transfusion and contrast-induced acute kidney injury (CI-AKI) rates for subgroups 
defined by gender and perforation    
1B. Risk adjusted transfusion associated with coronary perforation in men and women    
 
127x103mm (300 x 300 DPI)  
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Risk adjusted mortality, transfusion and contrast-induced acute kidney injury (CI-AKI) rates for subgroups 
defined by gender and perforation    
1C. Risk adjusted CI-AKI associated with coronary perforation in men and women    
 
127x110mm (300 x 300 DPI)  
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Figure 2: Long term mortality of propensity matched patients with and without coronary artery perforation 
among those discharged alive after PCI  
 
127x123mm (300 x 300 DPI)  
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Supplementary Table 1: Covariates included in propensity matching of patients with and without 
coronary artery perforation 
 
PCI Indication: 
1) Immediate PCI for STEMI 
2) PCI for STEMI (Unstable) 
3) PCI for STEMI (Stable) 
4) PCI for STEMI, stable after successful full-dose 
Thrombolysis) 
5) Rescue PCI for STEMI (after failed full-dose 
lytics) 
6) PCI for high risk Non-STEMI or unstable 
angina 
7) Staged PCI 
8) Other 
CAD presentation: 
1) No symptom, no angina 
2) Symptom unlikely to be ischemic 
3) Stable angina 
4) Unstable angina 
5) Non-STEMI 
6) STEMI or equivalent 
PCI status: 
1) elective              2) urgent 
3) emergency         4) salvage 
Admission source: 
1) admitted from emergency department 
2) transfer 
3) other 
Smoking status (current smoker) Prior CABG 
Hypertension Height 
Dyslipidemia Weight 
Family history of CAD Currently on dialysis 
Prior MI Prior cerebrovascular disease 
Prior heart failure Prior peripheral artery disease 
Prior valve surgery Chronic lung disease 
Prior PCI Diabetes 
Heart failure within the past 2 weeks LV ejection fraction less than 40% 
Pre-procedural Hemoglobin Race (white, black, Asian, other – allowing 
selection of multiple categories) 
Cardiomyopathy and/or left ventricular 
dysfunction 
Prior cardiogenic shock (within 24 hours) 
Prior cardia  arrest (within 24 hours) Cardiogenic shock at start of PCI 
procedure 
Age Gender 
Predicted patient mortality risk based on BMC2 
mortality risk model. 
 
CAD: coronary artery disease, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary artery 
bypass grafting, NSTEMI: non-ST segment elevation myocardial infarction, STEMI: ST segment elevation myocardial 
infarction, BMC2: Blue Cross Blue Shield of Michigan Cardiovascular Consortium, LV: left ventricular 
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Supplementary Table 2: Comparison of propensity matched cohorts of patients with and without 
coronary artery perforation 
 
 
Characteristic No Perforation Perforation p-value 
Absolute 
Standard 
Difference 
Age 74.74 ± 9.51 74.16 ± 10.75 p = 0.597 5.75 
Sex     
   Male 483/1,030 (46.9%) 50/103 (48.5%) p = 0.749 3.30 
   Female 547/1,030 (53.1%) 53/103 (51.5%) p = 0.749 3.30 
Height 166.37 ± 10.69 166.63 ± 11.26 p = 0.822 2.38 
Weight 80.45 ± 19.71 80.83 ± 20.16 p = 0.856 1.90 
Race     
   White 978/1,030 (95.0%) 98/103 (95.1%) p = 0.931 0.90 
   Black  32/1,030 (3.1%) 3/103 (2.9%) p = 0.913 1.14 
   Asian 8/1,030 (0.8%) 1/103 (1.0%) p = 0.832 2.09 
Admit Source     
   Emergency department 464/1,030 (45.0%) 45/103 (43.7%) p = 0.791 2.74 
  Transfer in from another acute care facility 239/1,030 (23.2%) 26/103 (25.2%) p = 0.641 4.76 
   Other 327/1,030 (31.7%) 32/103 (31.1%) p = 0.888 1.46 
Current/Recent Smoker  154/1,030 (15.0%) 15/103 (14.6%) p = 0.916 1.10 
Hypertension 925/1,030 (89.8%) 92/103 (89.3%) p = 0.877 1.59 
Dyslipidemia 862/1,030 (83.7%) 86/103 (83.5%) p = 0.960 0.52 
Family History of Premature CAD 197/1,030 (19.1%) 19/103 (18.4%) p = 0.867 1.74 
Prior MI 406/1,030 (39.4%) 42/103 (40.8%) p = 0.788 2.77 
Prior Heart Failure 214/1,030 (20.8%) 22/103 (21.4%) p = 0.890 1.43 
Prior PCI 447/1,030 (43.4%) 46/103 (44.7%) p = 0.805 2.54 
Prior CABG 259/1,030 (25.1%) 27/103 (26.2%) p = 0.812 2.44 
Cerebrovascular Disease 258/1,030 (25.0%) 25/103 (24.3%) p = 0.862 1.80 
Peripheral Arterial Disease 282/1,030 (27.4%) 29/103 (28.2%) p = 0.866 1.73 
Chronic Lung Disease 210/1,030 (20.4%) 21/103 (20.4%) p = 1.000 0 
Diabetes Mellitus 440/1,030 (42.7%) 44/103 (42.7%) p = 1.000 0 
CAD Presentation     
   No angina 24/1,030 (2.3%) 2/103 (1.9%) p = 0.802 2.69 
   Symptom unlikely to be ischemic 18/1,030 (1.7%) 2/103 (1.9%) p = 0.886 1.44 
   Stable angina 95/1,030 (9.2%) 10/103 (9.7%) p = 0.871 1.66 
   Unstable angina 434/1,030 (42.1%) 43/103 (41.7%) p = 0.939 0.79 
   NSTEMI 254/1,030 (24.7%) 26/103 (25.2%) p = 0.896 1.35 
   STEMI  205/1,030 (19.9%) 20/103 (19.4%) p = 0.906 1.22 
PCI Status     
   Elective 350/1,030 (34.0%) 36/103 (35.0%) p = 0.843 2.04 
   Urgent 481/1,030 (46.7%) 48/103 (46.6%) p = 0.985 0.19 
   Emergency 199/1,030 (19.3%) 19/103 (18.4%) p = 0.830 2.23 
PCI Indication     
   Immediate PCI for STEMI 156/1,030 (15.1%) 16/103 (15.5%) p = 0.917 1.08 
   PCI for STEMI (Unstable, >12 hours from symptom onset) 49/1,030 (4.8%) 4/103 (3.9%) p = 0.689 4.30 
   PCI for high risk NSTEMI or unstable angina 581/1,030 (56.4%) 59/103 (57.3%) p = 0.865 1.76 
   Staged PCI 9/1,030 (0.9%) 1/103 (1.0%) p = 0.920 1.02 
   Other 235/1,030 (22.8%) 23/103 (22.3%) p = 0.911 1.16 
Heart Failure within two weeks  193/1,030 (18.7%) 19/103 (18.4%) p = 0.942 0.75 
Cardiomyopathy or left ventricular systolic dysfunction 124/1,030 (12.0%) 13/103 (12.6%) p = 0.863 1.77 
Cardiogenic Shock at start of PCI 50/1,030 (4.9%) 5/103 (4.9%) p = 1.000 0 
Pre-Procedure Hemoglobin 12.73 ± 1.80 12.73 ± 1.71 p = 0.975 0.32 
CAD: coronary artery disease, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, NSTEMI: 
non-ST segment elevation myocardial infarction, STEMI: ST segment elevation myocardial infarction 
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Supplementary Table 3: Baseline mean predicted risks, outcomes, and adjusted odds ratios of 
patients with and without coronary artery perforation 
OR=odds ratio, CI-AKI=contrast-induced acute kidney injury, CI=confidence interval, O/E = 
observed/expected 
 
Estimated baseline risk  
of death 
Estimated baseline 
risk  of CI-AKI 
Estimated baseline 
risk of transfusion 
No Perforation 1.51% 2.70% 2.94% 
Perforation 2.54% 3.28% 4.09% 
p-value p = .001 p = .026 p < .001 
    
 Mortality CI-AKI incidence 
Transfusion 
incidence 
No Perforation 1.50% 2.68% 2.91% 
Perforation 6.56% 7.95% 12.64% 
    
Overall rate: 1.52% 2.70% 2.95% 
    
O/E ratio: Death CI-AKI Transfusion 
No Perforation 0.99 0.99 0.99 
Perforation 2.58 2.42 3.09 
Adjusted OR 
5.00 (95% CI  3.42 – 
7.31) 
3.25 95% CI 2.30 – 
4.58) 
5.26 (95% CI 4.03-
6.87) 
p-value: p < .001 p < .001 p < .001 
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1A-C: Overall incidence of CAP, proportion of PCI performed for treatment of CTO and incidence of CAP 
among CTO cases over a 5-year period    
Supplementary Figure 1A: Perforation rate by year  
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1A-C: Overall incidence of CAP, proportion of PCI performed for treatment of CTO and incidence of CAP 
among CTO cases over a 5-year period  
Supplementary Figure 1B: Treated CTO lesion rate by year  
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1A-C: Overall incidence of CAP, proportion of PCI performed for treatment of CTO and incidence of CAP 
among CTO cases over a 5-year period  
Su plementary Figure 1C: Perforation rate by year in patients with a treated CTO lesion  
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Subject: JINT041916-0818 Decision Letter 
 
"Coronary Artery Perforations after Contemporary Percutaneous Coronary Interventions: 
Evaluation of Incidence, Risk Factors, Outcomes and Predictors of Mortality" 
 
Dear Dr. Gurm, 
 
Thank you for your recent manuscript submission to JACC: Cardiovascular Interventions. 
Unfortunately, after careful consideration by the editors and by expert external reviewers, the 
consensus is that its priority is not sufficient to warrant publication. 
 
The comments of the reviewers are enclosed for your information. 
 
We recognize the thought and effort that went into your work. Regrettably, we are able to 
publish less than one-fifth of the papers we receive, and must decline many of considerable 
merit. Thank you for your interest in the journal, and we look forward to reviewing other 
submissions from you in the future. 
 
Sincerely, 
 
Spencer B. King III, MD, MACC 
Editor-in-Chief 
JACC: Cardiovascular Interventions 
Heart House, 2400 N Street NW, Washington, DC, 20037 
Ph: 202-375-6136 
Fax: 202-375-6819 
Email: jaccint@acc.org 
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Associate Editor (Comments for the Author): 
 
There are discrepancies in your numbers and percentages. These should all be reviewed and 
reconciled. 
 
Reviewer #1 (Comments for the Author (Required)): 
 
The authors submit and interesting retrospective analysis of coronary perforation from a very 
large database. Perhaps they would consider whether attention to the following might strengthen 
their paper: 
 
1. Please clarify some numbers: in the results section you state that 563 patients, or 0.37% of all 
PCI cases during the enrollment window, had a coronary performation. In the discussion you 
state that your paper 'adds...more than 600 patients with CAP' (pg 10) and on pg 9 you state that 
'the incidence of CAP in our population was 0.67%'. Why do these numbers differ? 
 
2. I understand the limitations of a retrospective database study such as this in gathering more 
granular data but such is tremendously important to interventionalists. For starts, who entered the 
data into the database and what source documentation was used? 
 
3. You suggest that additional data might be sampled, could not the procedure reports be 
gathered? Could claims data be used to determine if pericardiocentesis and or cardiac surgery 
was performed during the index hospitalization? 
 
4. The observation that less than 10% of the patients received a covered stent suggests that most 
of perforations identified might have been more 'incidental' than life threating. Of course there 
are cases, especially CTO procedures using epicardial collaterals in which a covered stent might 
not be deliverable. When you say covered stents were utilized does this imply that the device 
was actually deployed successfully or migh it also include when such a stent was asked for and 
taken out of the box but never successfully deployed? 
 
5. Can you provide data as to how many of the patients died on the same day as the index 
procedure? 
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Reviewer #2 (Comments for the Author (Required)): 
 
The study by Parsh et al is a retrospective report from the BCBS PCI database of Michigan. The 
authors sought to evaluate the incidence, clinical predictors, and in hospital prognosis of pts 
undergoing PCI who had coronary perforations (CAP). The authors observed an incidence of 
0.63%, with PCI of CTO as the strongest predictor of CAP. CAP was also associated with higher 
rates of transfusion, AKI, and death. This represents one of the largest contemporary registry 
reports of CAP, and is thus of potential interest. There are a few issues that merit discussion: 
 
1. The Ellis classification of CAP has been shown to correlate with adverse outcomes, with class 
I CAP having a more benign outcome. Although the authors acknowledge this as a limitation this 
study would be strengthened by stratifying outcomes and predictors using the Ellis classification. 
 
2. In the absence of more detailed lesion characteristics such as extent of calcification, lesion 
length, reference diameters etc evaluating clinical and limited procedural characteristics and their 
influence on CAP and outcomes is potentially biased. Including known important lesion 
characteristics would substantially strengthen the study (not sure why this information is not 
available since one would assume most sites also participate in the NCDR which does collect 
this type of information). 
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Associate Editor: 
  
There are discrepancies in your numbers and percentages. These should all be reviewed and 
reconciled.  
 
We apologize for these errors. All numbers have been verified from the original data 
and then corrected in the manuscript. In addition, our data has been updated to include 
all patients undergoing PCI in the state of Michigan from January 2010 and December 
2015. 
 
Page 11: 
The incidence of CAP in our population was 0.34%, confirming that CAP remains an 
uncommon event.  
 
Page 11: 
 
Our study adds to the existing literature by identifying more than 600 patients with CAP.  
 
Reviewer #1  
  
The authors submit and interesting retrospective analysis of coronary perforation from a 
very large database. Perhaps they would consider whether attention to the following 
might strengthen their paper:  
  
1. Please clarify some numbers: in the results section you state that 563 patients, or 
0.37% of all PCI cases during the enrollment window, had a coronary perforation. In the 
discussion you state that your paper 'adds...more than 600 patients with CAP' (pg 10) 
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and on pg 9 you state that 'the incidence of CAP in our population was 0.67%'. Why do 
these numbers differ?  
 
We again apologize for these errors. As noted above in response to the associate editor  
comments, all numbers have been verified. 
  
2. I understand the limitations of a retrospective database study such as this in gathering more 
granular data but such is tremendously important to interventionalists. For starts, who entered 
the data into the database and what source documentation was used?  
 
The data collected by the BMC2 collaborative registry is abstracted by trained personnel  
at the individual member hospitals directly from the medical record and is subject to  
periodic random audit of 2% of cases, and 100% audit of all cases resulting in mortality. 
 
3. You suggest that additional data might be sampled, could not the procedure reports be 
gathered? Could claims data be used to determine if pericardiocentesis and or cardiac surgery 
was performed during the index hospitalization?  
 
The BMC2 registry does collect data on whether coronary artery bypass grafting was 
performed during admission and we have added this data to the manuscript. 
Performance of pericardiocentesis is not recorded and procedure reports are not 
available for further review. 
 
Page 8: 
Of the 625 patients who developed CAP, 22 (3.52%) underwent post-procedural CABG, 
of which 2 (9.90%) died prior to discharge.  
 
4. The observation that less than 10% of the patients received a covered stent suggests that 
most of perforations identified might have been more 'incidental' than life threating. Of course 
there are cases, especially CTO procedures using epicardial collaterals in which a covered stent 
might not be deliverable. When you say covered stents were utilized does this imply that the 
device was actually deployed successfully or might it also include when such a stent was asked 
for and taken out of the box but never successfully deployed?  
 
We appreciate the reviewer’s comment and would like to clarify the coding of covered 
stents in the BMC2 registry. Per the coder dictionary, when the use of a covered stent is  
recorded, this refers only to cases where covered stents were actually deployed (and 
not merely taken out of the box). We have clarified this as follows: 
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 Page 10: 
 
Of the 625 cases of CAP, covered stents were successfully deployed in 70 (11.2%). Of the 
70 CAP cases where covered stents were used, 12 (17.1%) patients died versus 29 
deaths (5.23%) among 555 patients where covered stents were not utilized.  
 
5. Can you provide data as to how many of the patients died on the same day as the index 
procedure?  
 
We appreciate the reviewer’s suggestion to include this data. 
Page 9: 
Thirteen of the 41 perforation deaths (31.7%) occurred in the catheterization lab, and 
20 deaths occurred on the same calendar date as the index PCI procedure (48.8%). 
 
Reviewer #2  
 
The study by Parsh et al is a retrospective report from the BCBS PCI database of Michigan. The 
authors sought to evaluate the incidence, clinical predictors, and in hospital prognosis of pts 
undergoing PCI who had coronary perforations (CAP). The authors observed an incidence of 
0.63%, with PCI of CTO as the strongest predictor of CAP. CAP was also associated with higher 
rates of transfusion, AKI, and death. This represents one of the largest contemporary registry 
reports of CAP, and is thus of potential interest. There are a few issues that merit discussion:  
 
1. The Ellis classification of CAP has been shown to correlate with adverse outcomes, with class I 
CAP having a more benign outcome. Although the authors acknowledge this as a limitation this 
study would be strengthened by stratifying outcomes and predictors using the Ellis 
classification.  
 
We appreciate the reviewer’s comments and we do acknowledge that lack of data on  
Ellis classification of CAP is a limitation of our study. Going forward, there is interest in  
integrating Ellis classification into the BMC2 database as this would allow for more 
robust investigation of CAP. 
 
2. In the absence of more detailed lesion characteristics such as extent of calcification, lesion 
length, reference diameters etc evaluating clinical and limited procedural characteristics and 
their influence on CAP and outcomes is potentially biased. Including known important lesion 
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available since one would assume most sites also participate in the NCDR which does collect this 
type of information).  
 
We appreciate the reviewer’s comments. We have extended our analysis to include 
lesions characteristic information that is available through our BMC2 database. In 
addition to investigating the risk of CAP in treated chronic total occlusions and type C 
lesions, risk of CAP in bifurcation lesions and lesions with thrombus was studied and is 
presented in Table 2.   
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Table 2: Perforations by device type and type of coronary lesion  
 
 
Percent of cases 
where device 
was used or 
lesion variable 
present 
Perforation rate 
in cases with 
device or lesion 
variable 
Perforation rate 
in cases without 
device or lesion 
variable 
Odds Ratio 
P-value      
(Fisher exact 
test) 
Intracoronary device type      
Thrombectomy 5.67% 0.31% 0.33% 0.940 0.850 
Cutting Balloon 4.92% 0.42% 0.32% 1.301 0.155 
Atherectomy 1.03% 0.98% 0.32% 3.051 < 0.001 
Bare Metal Stent 17.69% 0.32% 0.33% 0.952 0.731 
Drug Eluting Stent 72.13% 0.26% 0.50% 0.524 < 0.001 
Extraction Catheter 3.51% 0.18% 0.33% 0.535 0.043 
Embolic Protection 2.10% 0.42% 0.33% 1.281 0.357 
Laser 0.13% 2.82% 0.33% 8.876 < 0.001 
Type of coronary lesion      
Chronic Total Occlusion 1.91% 1.91% 0.30% 6.514 < 0.001 
Type C lesion 56.62% 0.36% 0.29% 1.242 0.017 
Thrombus Present 15.91% 0.26% 0.34% 0.761 .036 
Bifurcation Lesion 5.67% 0.31% 0.33% 0.940 0.850 
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Abstract 
 
Objectives:  We sought to evaluate the incidence, risk factors, in-hospital and long term 
outcomes and predictors of mortality of coronary artery perforations (CAP) in the contemporary 
percutaneous coronary intervention (PCI) era. 
Background: CAP is a rare but serious complication of PCI associated with increased risk of 
morbidity and mortality.  
Methods: We included 181,590 procedures performed across 47 hospitals in Michigan from 
1/1/2010-12/31/2015. Endpoints evaluated included the incidence of CAP and its association 
with in-hospital outcomes. Logistic regression analysis was utilized to determine independent 
risk factors for CAP and to examine whether the effect of CAP on mortality varied by gender.  
Results: CAP occurred in 625 (0.34%) of patients. Independent predictors for CAP included 
older age, peripheral arterial disease, presence of left ventricular dysfunction or cardiomyopathy, 
lower body mass index, pre-PCI insertion of a mechanical ventricular support device, treatment 
of complex lesions (Type C), and treatment of chronic total occlusions, the latter of which was 
the strongest predictor of perforation (adjusted odds ratio 7.01, p < 0.001). After adjusting for 
baseline risk, the incidence of adverse outcomes remained substantially greater in patients with a 
perforation, with an adjusted odds ratio estimate of 5.00 for mortality (95% CI 3.42-7.31), 3.25 
for acute kidney injury (95% CI 2.30-4.58), and 5.26 for transfusion (95% CI 4.03-6.87) (all p < 
0.001). Perforation was associated with a higher mortality in women than men (interaction p-
value = 0.01).  
Conclusions: CAP is a rare complication but is associated with high morbidity and mortality 
especially in women. Further investigation is warranted to determine why women fare worse 
after CAP. 
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Condensed Abstract 
In this retrospective study including 181,590 PCI procedures performed in the state of Michigan, 
treatment of CTO was the strongest independent predictor of CAP. Development of CAP was 
associated with increased risk of inpatient and long term mortality, transfusion and acute kidney 
injury. We also found that women fare worse than men after development of CAP with a greater 
risk of inpatient mortality. Further prospective investigation is required to further identify risk 
factors for the poor prognosis after CAP, the etiology of possible gender discrepancies in 
outcomes and to assess the efficacy of various treatment options for CAP. 
Key words: perforation, gender, mortality 
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Abbreviations: 
1. CAP: Coronary artery perforations 
2. PCI: percutaneous coronary interventions 
3. CABG: coronary artery bypass grafting 
4. CTO: Chronic total occlusion 
5. BMC2: Blue Cross Blue Shield of Michigan Cardiovascular Consortium  
6. MVC: Michigan Value Collaborative 
7. BCBSM: Blue Cross Blue Shield of Michigan 
8. CI-AKI: Contrast-induced acute kidney injury  
9. IABP: intra-aortic balloon pump  
10. STEMI: ST-segment elevation myocardial infarction 
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Introduction 
The incidence of coronary artery perforation (CAP) during percutaneous coronary 
interventions (PCI) is estimated at 0.1% to 0.84%.
1
 Although rare, CAP is associated with an 
increased risk of adverse outcomes including tamponade, myocardial infarction, need for 
emergency coronary artery bypass grafting (CABG), and death.
2-4
 The majority of studies thus 
far have included a modest number of patients and it is unclear which pre-procedural patient 
factors are associated independently with an increased risk of CAP as well as which factors 
increase the risk of adverse outcomes after CAP. In addition, given improvement of equipment 
and therapies, advancing age of the population and changing guidelines, PCI utilization in certain 
higher risk subgroups, including the elderly or those with chronic total occlusions (CTO), has 
been increasing.
5-8 
 This study represents a large cohort of patients developing CAP after PCI and 
provides an updated analysis of the incidence, risk factors, and inpatient and long term outcomes 
associated with CAP in contemporary practice. 
Methods 
We included data from patients undergoing PCI at 47 hospitals participating in the Blue 
Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The details of the BMC2 
registry and its data collection and auditing process have been described previously.
9
 Briefly, 
procedural data on all patients undergoing PCI at participating hospitals are collected using 
standardized data collection forms. Baseline data include clinical, demographic, procedural, and 
angiographic characteristics as well as medications used before, during, and after the procedure, 
and in-hospital outcomes. All data elements have been prospectively defined, and the protocol is 
approved by local institutional review boards at each hospital. In addition to a random audit of 
2% of all cases, medical records of all patients undergoing multiple procedures or coronary 
artery bypass grafting and of patients who died in the hospital are reviewed routinely to ensure 
data accuracy.  
 The study population for this analysis included all consecutive patients who underwent 
PCI between January 2010 and December 2015.  If a patient underwent more than one PCI 
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procedure during a hospital stay, only procedural data reflecting the earliest procedure is 
included in this analysis. For a subset of Medicare beneficiaries in the dataset, 90-day 
readmission and long term survival data were available through indirect matching on admission, 
discharge and procedure dates for the index hospitalization, patient gender and date of birth, and 
hospital and operator NPI numbers with Medicare data for PCI episodes in collaboration with the 
Michigan Value Collaborative (MVC).
10, 11
  
Study endpoints 
Inpatient mortality was defined as mortality from any cause during the initial 
hospitalization following PCI. Contrast-induced acute kidney injury (CI-AKI) was defined as an 
increase in pre-procedural to post-procedural serum creatinine ≥ 0.5 mg/dl, since this definition 
has been strongly associated with inpatient mortality and new requirement for dialysis.
12
 Pre-
procedural serum creatinine values were measured within 30 days prior to PCI, with the value 
closest to time of PCI chosen as the baseline value. Peak post-procedural serum creatinine was 
defined as the highest value after PCI and prior to the next procedure or discharge. 
Statistical analysis 
Univariate comparisons were performed using student T-tests for continuous measures, 
and Fisher exact tests for dichotomous measures.  The Cochrane-Armitage trend test was used to 
assess whether the rate of CAP and the rate of treatment of CTO lesions changed over time.  
Multivariate logistic regression with stepwise variable selection using Akaike Information 
Criteria was utilized to identify pre-procedural clinical and demographic patient characteristics 
associated with the development of CAP.  Patient characteristics included as candidate predictors 
were chosen based on both significant univariate differences as well as associations with CAP 
observed in previous studies.
1-3
 
Pre-procedural patient risk of in-hospital outcomes including mortality, transfusion, and 
CI-AKI were estimated using the current BMC2 random Forest risk models from baseline patient 
clinical and demographic characteristics. The models are implemented for patient pre-procedural 
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risk prediction, and model inputs are described at the SCAI/BMC2 PCI online risk prediction 
tool available at both the BMC2 https://bmc2.org/calculators/multi and SCAI  
http://www.scai.org/PCIRiskAssessmentTools/default.aspx websites.
13-16
  Risk adjusted 
mortality, transfusion, and CI-AKI rates were estimated for sub-groups by the overall 
collaborative outcome incidence multiplied by the ratio of observed to expected outcome rates 
for the subgroup (overall rate * O/E ratio for subgroup).   
The association of CAP with adverse outcomes of inpatient mortality, need for 
transfusion and development of CI-AKI was assessed using multivariate logistic regression 
models adjusting for baseline patient risk.  To assess whether the effect of CAP on outcomes 
potentially varied by gender, likelihood ratio tests were utilized to determine whether inclusion 
of a gender by CAP interaction term significantly improved model fit. 
In the subset of Medicare patients for which long term survival data was available, 
propensity score matching was employed to account for baseline patient clinical and 
demographic variables that could confound the analysis of the impact of CAP on post-discharge 
survival. Logistic regression was utilized to construct the propensity score, and each CAP patient 
was matched to 10 similar non-CAP cases without replacement using a greedy algorithm. 
Variables included in the propensity score model and comparison of the cohorts are included in 
Supplementary Table 1 and 2. Kaplan-Meier incidence curves were used to visualize post 
discharge survival by group, and Cox proportional hazard regression was utilized to assess 
differences in survival between groups.  
Results 
 
Baseline demographics and clinical characteristics  
 
Between January 2010 and December 2015, 181,590 patients underwent PCI in the state 
of Michigan and were included in this analysis.  Of these patients, 625 (0.34%) suffered CAP 
during the PCI procedure, and 41 (6.56%) patients with perforation died prior to discharge.  The 
rate of perforation overall was relatively stable over the 6 years included in the analysis 
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(Supplementary Figure 1A).  The proportion of PCI cases where a CTO lesion was treated 
increased in statistically significant fashion over this same 6-year period, from 1.6% to 2.8% of 
all cases (Cochran Armitage trend test p value < 0.001), while the incidence of perforation 
among the subgroup of CTO cases did not demonstrate a statistically significant trend (Cochrane 
Armitage trend test p-value=0.06) (Supplementary Figure 1B-C).  
Baseline clinical, demographic and procedural characteristics for patients with and 
without perforation are provided in Table 1.  Patients with CAP were older, more likely to be 
female, have peripheral arterial disease or heart failure, require intra-aortic balloon pump (IABP) 
or other mechanical ventricular support prior to PCI, and to be in cardiogenic shock at the start of 
the procedure compared to those without CAP.  Conversely, patients with perforations were less 
likely to have diabetes.   
 Of the 625 patients who developed CAP, 22 (3.52%) underwent post-procedural 
CABG, of which 2 (9.90%) died prior to discharge.  
Association of CAP with intracoronary devices and coronary lesion variables 
Among the 625 cases of CAP, 524 (83.8%) involved only one treated vessel and these 
cases were utilized to examine the association of CAP with specific devices or coronary lesion 
variables (Table 2). Lesion length was significantly longer in vessels that developed CAP (29.24 
± 13.46 mm) compared to those without CAP (23.74 ± 13.46 mm) (p-value<0.001). The use of 
atherectomy and laser were each associated with significantly higher rates of CAP with odds 
ratio of 3.05 and 8.88, respectively (both p<0.001). When analyzing the treatment of specific 
coronary lesion variables, CAP occurred in 1.91% of patients with a treated CTO lesion 
compared to only 0.3% of patients without CTO, and a CTO PCI was the strongest univariate 
predictor of increased risk of CAP (odds ratio 6.51, Fisher Exact test p-value < 0.001). 
Predictors of CAP 
Multivariate stepwise logistic regression identified older age, peripheral arterial disease, 
presence of left ventricular dysfunction or cardiomyopathy, treatment of high complexity (type 
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C) lesions, treatment of CTO, and use of a mechanical ventricular support prior to PCI as 
predictors of CAP (Table 3). Treatment of CTO remained associated with the greatest estimated 
risk of CAP after adjusting for other covariates, with patients treated for CTO having a seven-
fold greater odds of developing CAP, odds ratio 7.01 (95% CI 5.48 – 8.98; p – value < 0.001). 
Greater height, higher body mass index and presence of diabetes were associated with a lower 
risk for the development of CAP.  
In-hospital outcomes 
Mean baseline risk estimates and outcomes of patients with and without perforations are 
provided in Supplementary Table 3.  Mean predicted risks were significantly higher in patients 
with perforation, reflecting a greater burden of comorbidites in these patients.  After adjusting for 
baseline predicted risk in a logistic regression model, patients with perforations remained at a 
substantially higher risk of adverse outcomes, with an adjusted odds ratio estimate of 5.00 (95% 
CI 3.42 – 7.31) for mortality, 3.25 (95% CI 2.30 – 4.58) for CI-AKI, and 5.26 (95% CI 4.03 – 
6.87) for transfusion (all p < 0.001). 
Predictors of in-hospital mortality 
Table 4 provides a comparison of baseline and procedural patient characteristics of 
patients with CAP who died during the hospitalization and those discharged alive.  Among the 
41 patients that died, multiple pre-procedural patient characteristics, clinical presentations, 
procedural outcomes and complications occurred more frequently including: older age, female 
gender, ST-segment elevation myocardial infarction (STEMI) presentation, recent heart failure, 
cardiogenic shock or cardiac arrest, and pre-PCI insertion of IABP or other mechanical 
ventricular support. Of the 41 perforation patients who died, 29 (70.7%) were female, compared 
to only 40.1% of those discharged alive (p <0.001).   Thirteen of the 41 perforation deaths 
(31.7%) occurred in the catheterization lab, and 20 deaths occurred on the same calendar date as 
the index PCI procedure (48.8%). 
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Figure 1 (a, b and c) provides risk adjusted mortality, CI-AKI, and transfusion rates for 
subgroups defined by gender and perforation.  The effect of CAP on mortality was significantly 
greater in women compared to men when assessed by multivariate logistic regression model 
(gender by perforation interaction p-value = 0.01).  No significant CAP by gender interaction 
was observed for the CI-AKI (p = 0.32) or transfusion (p = 0.50). 
Subsequent analysis stratified by gender demonstrated a statistically significant increase 
in mortality with CAP in both men with adjusted OR=2.70 (95% CI: 1.37 - 5.30; p-value = 
0.004) and women with an OR= 7.32 (95% CI: 4.60 – 11.65; p<0.001).   By contrast, no 
significant weight by CAP interaction was observed in the mortality model (p = 0.80), indicating 
no significant evidence that the relationship between CAP and mortality varied across the 
spectrum of patient weights  
Of the 625 cases of CAP, covered stents were successfully deployed in 70 (11.2%). Of 
the 70 CAP cases where covered stents were used, 12 (17.1%) patients died versus 29 deaths 
(5.23%) among 555 patients where covered stents were not utilized. After adjusting for predicted 
risk of death in logistic regression, the odds ratios for inpatient mortality for cases of CAP 
treated with covered stents vs. no covered stent was 4.46 (p < 0.001) likely related to the fact that 
covered stent use is reserved for perforations that are more likely to be hemodynamically 
significant. 
Long term outcomes 
Using propensity score matching, 1,030 Medicare patients without CAP having similar 
baseline clinical and demographic characteristics to the 103 available Medicare patients with 
CAP (Supplementary Tables 1 and 2) were selected. Median post-discharge follow-up in this 
cohort was 23 months for both groups, with 34 (33.0%) deaths observed among CAP patients, 
and 205 (19.9%) deaths among non-CAP patients during follow up. Kaplan-Meier survival 
curves with confidence band shading are provided in Figure 2. In Cox proportional hazards 
regression, CAP was associated with significantly greater mortality (HR = 1.63, p = .008). In 
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contrast to in-hospital mortality, no significant gender by CAP interaction was observed in Cox 
regression (p = 0.430), and women and men with CAP had comparable estimated mortality at 2 
years (men 31.1% (95% CI 14.4% - 44.6%), women 23.6% (95% CI 10.2% - 35.0%)). No 
significant difference was observed for 90-day readmission (30.1% for CAP, 23.8% no CAP, p = 
0.185) 
Discussion 
This study includes one of the largest patient cohorts describing the risk of CAP during 
PCI in contemporary practice. The incidence of CAP in our population was 0.34%, confirming 
that CAP remains an uncommon event. However, the high in-hospital mortality rate of 6.56% 
confirms the associated high mortality and highlights the need for further investigation into 
understanding risk factors, outcomes and potential therapies for this serious complication.  
Small retrospective studies have identified various patient and angiographic 
characteristics as potential risk factors for CAP including older age, female gender, presence of 
chronic kidney disease, hypertension, and previous PCI or CABG as well as angiographic 
characteristics such as type C lesions, chronic total occlusions, calcified lesions, and culprit 
lesions in the right coronary artery.
1-4
 In addition, certain procedural characteristics including a 
higher balloon to artery ratio and the use of atheroablative devices were shown in these limited 
studies to increase the risk of this serious event.
1, 3, 4
 
Our study adds to the existing literature by identifying more than 600 patients with CAP. 
Some factors that have been suggested to be associated with CAP were not found to be 
independently associated with CAP in this large study, including hypertension, chronic kidney 
disease and prior coronary artery bypass grafting.
3, 4
 However, consistent with prior studies, our 
analysis identified several patient and procedural characteristics as independent risk factors for 
CAP, including older age and treatment of chronic total occlusions.
2-4
 In fact, treatment of CTO 
was the strongest risk factor for CAP development, which is an important consideration as 
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recently there has been an increasing interest in treatment of these higher risk lesions as 
techniques and technology have improved.  
Consistent with prior work, we found CAP to be associated with an increased risk of in-
hospital mortality.
1, 2
 However, we also identified that CAP was associated with increased risk of 
long term mortality and with other adverse in-hospital outcomes, including development of CI-
AKI and the need for transfusion. Possible mechanisms to explain the increased risk of CI-AKI 
and need for transfusion include hemodynamic compromise related to development of 
complications of tamponade or myocardial infarction as well as need for additional procedures or 
surgical repair.   
Our study also demonstrated that the effect of CAP on mortality may vary by gender with 
our results indicating that perforation is significantly more deleterious in women than men.  The 
etiology of the increased risk of death in women with CAP is unknown but potentially relates to 
anatomical or hormonal differences between sexes. One hypothesis relates to a presumed smaller 
vessel diameter or differences in vessel wall thickness size in women that could increase the risk 
of development of CAP and/or higher grades of CAP.
17
 The influence of estrogen on coagulation 
factors and inflammatory markers has been proposed as a mechanism to explain the increased 
susceptibility for vascular injury. Our study did not examine the influence of smaller vessel size 
on the development of CAP, since the BMC2 database does not include information on vessel 
diameter.  
The manner in which CAP is treated is dependent on the severity of the CAP, often 
graded by Ellis type classification, and whether certain complications associated with CAP, such 
as tamponade, are present.
18
  Potential therapies include the use of prolonged balloon occlusion, 
deployment of covered stents, thrombin or gelfoam embolization, coils or CABG. We found that 
covered stents were utilized in the minority of patients with CAP, however these patients 
experienced higher rates of inpatient mortality. We hypothesize that this is related to the use of 
these therapies in more severe cases of CAP and that the worse outcomes in these patients are 
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related to this underlying higher grade perforation than the use of the covered stent itself. 
However, there is also evidence that covered stents are at higher risk for restenosis and 
thrombosis.
19
 We do not have data on the exact reason why these patients died and further 
investigation into optimal treatment of CAP is needed. 
There are several limitations to our study. First, our study was a retrospective analysis 
utilizing data from a large database which does not include details on the severity of CAP (such 
as Ellis type classification) or vessel size, which would be important to examine when attempting 
to identify the etiology of the potentially worse prognosis of CAP in women than men. In 
addition, various outcomes that may develop after CAP, including tamponade, need for 
emergency surgery or subsequent development of MI, could not be evaluated in our population 
based on database restrictions. Evaluating incidence and efficacy of various treatments for CAP 
was limited to assessing the use of covered stents in our population with CAP.  
In conclusion, CAP remains an uncommon but serious complication of PCI, associated 
with an increased incidence of inpatient mortality, CI-AKI and need for transfusion as well as 
long term mortality. Treatment of CTO lesions was the strongest independent predictor of CAP. 
Coronary artery perforations were more harmful in women than men in our study. Further 
investigation into the etiology of the poorer prognosis of CAP in women as well as efficacy of 
various therapies to treat CAP is needed. 
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Table 1: Characteristics of patients with and without coronary artery perforation 
 
Characteristic Coronary Perforation – no. (%) p-value 
 No 
N = 180,965 
Yes 
N = 625 
 
Demographic   
Age (years) ± SD 65.08 ± 12.02 67.35 ± 12.04 p < 0.001 
Female gender 60,349 (33.3%) 263 (42.1%) p < 0.001 
Current or recent smoker 52,677 (29.1%) 177 (28.4%) p = 0.696 
Height (cm) 171.15 ± 10.59 168.95 ± 10.86 p < 0.001 
Weight (kg) 89.70 ± 21.43 84.21 ± 19.84 p < 0.001 
Historical    
Hypertension 154,589 (85.5%) 553 (88.8%) p = 0.019 
Dyslipidemia 148,315 (82.0%) 516 (82.7%) p = 0.668 
Diabetes Mellitus 69,556 (38.4%) 221 (35.4%) p = 0.113 
Peripheral Arterial Disease 29,069 (16.1%) 126 (20.2%) p = 0.005 
Prior MI 63,507 (35.1%) 244 (39.0%) p = 0.039 
Prior PCI 82,465 (45.6%) 294 (47.0%) p = 0.464 
Prior CABG 33,415 (18.5%) 136 (21.8%) p = 0.034 
Cardiomyopathy or Left Ventricular 
Systolic Dysfunction 
19,177 (10.6%) 91 (14.6%) p = 0.001 
Procedural    
PCI Status: Elective 66,218 (36.6%) 237 (38.0%) p = 0.478 
PCI Status: Urgent 83,790 (46.3%) 287 (46.0%) p = 0.868 
PCI Status: Emergency 30,498 (16.9%) 96 (15.4%) p = 0.325 
PCI Status: Salvage 364 (0.2%) 4 (0.6%) p = 0.015 
Arterial Access Site: Radial 37,473 (20.7%) 123 (19.7%) p = 0.538 
Pre-PCI insertion of IABP or other 
mechanical ventricular support device 
2,467 (1.4%) 25 (4.0%) p < 0.001 
Pre-PCI Left Ventricular Ejection 
Fraction ± SD 
51.90 ± 12.84 49.89 ± 14.42 p = 0.003 
Cardiogenic Shock at Start of PCI 3,765 (2.1%) 24 (3.8%) p = 0.002 
 
SD: standard deviation, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass 
grafting, IABP: intraaortic balloon pump 
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Table 2: Perforations by device type and type of coronary lesion  
 
 
Percent of cases 
where device 
was used or 
lesion variable 
present 
Perforation rate 
in cases with 
device or lesion 
variable 
Perforation rate 
in cases without 
device or lesion 
variable 
Odds Ratio 
P-value      
(Fisher exact 
test) 
Intracoronary device type      
Thrombectomy 5.67% 0.31% 0.33% 0.940 0.850 
Cutting Balloon 4.92% 0.42% 0.32% 1.301 0.155 
Atherectomy 1.03% 0.98% 0.32% 3.051 < 0.001 
Bare Metal Stent 17.69% 0.32% 0.33% 0.952 0.731 
Drug Eluting Stent 72.13% 0.26% 0.50% 0.524 < 0.001 
Extraction Catheter 3.51% 0.18% 0.33% 0.535 0.043 
Embolic Protection 2.10% 0.42% 0.33% 1.281 0.357 
Laser 0.13% 2.82% 0.33% 8.876 < 0.001 
Type of coronary lesion      
Chronic Total Occlusion 1.91% 1.91% 0.30% 6.514 < 0.001 
Type C lesion 56.62% 0.36% 0.29% 1.242 0.017 
Thrombus Present 15.91% 0.26% 0.34% 0.761 .036 
Bifurcation Lesion 5.67% 0.31% 0.33% 0.940 0.850 
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Table 3: Predictors of coronary artery perforation selected by stepwise logistic regression. 
 
 
 Odds Ratio P-value 95% Confidence Interval 
Age (per 5 year increase) 1.05 0.005 1.015-1.089 
Height (per 5 cm increase) 0.91 < 0.001 0.872-0.941 
BMI (per 1 unit increase) 0.98 0.001 0.965-0.991 
PAD 1.21 0.064 0.989-1.483 
Diabetes 0.86 0.090 0.723-1.024 
Cardiomyopathy or LV 
dysfunction 
1.30 0.026 1.032-1.633 
IABP or MV support device 
implanted prior to PCI 
2.04 0.002 1.302-3.207 
Pre-PCI creatinine 0.90 0.061 0.803-1.005 
Type C/high complexity lesion 1.15 0.100 0.973-1.364 
CTO lesion 7.01 < 0.001 5.478-8.980 
Cardiogenic shock at start of PCI 1.41 0.138 0.896-2.211 
 
BMI: body mass index, PAD: peripheral arterial disease, LV: left ventricle, MV: mechanical 
ventricular, CTO: chronic total occlusions 
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Table 4: Characteristics of patients with coronary artery perforations who were discharged alive versus deceased 
 
Characteristic 
Discharged alive 
N = 584 
In-hospital death 
N = 41 
p-value 
Absolute 
Standard 
Difference 
Demographic     
Age ± SD 66.98 ± 11.94 72.66 ± 12.28 p = 0.006 46.87 
Female Gender 234 (40.1%) 29 (70.7%) p < 0.001 64.85 
Current or recent smoker 162 (27.8%) 15 (36.6%) p = 0.230 18.81 
Historical     
Hypertension 518 (89.0%) 35 (85.4%) p = 0.476 10.90 
Dyslipidemia 487 (83.5%) 29 (70.7%) p = 0.036 30.84 
Diabetes Mellitus 207 (35.4%) 14 (34.1%) p = 0.867 2.73 
Prior MI 226 (38.7%) 18 (43.9%) p = 0.509 10.58 
Prior PCI 279 (47.8%) 15 (36.6%) p = 0.165 22.80 
Prior CABG 134 (22.9%) 2 (4.9%) p = 0.007 54.08 
CAD Presentation     
STEMI or equivalent 77 (13.2%) 13 (31.7%) p = 0.001 45.53 
Heart failure within two weeks 87 (14.9%) 14 (34.1%) p = 0.001 45.91 
Cardiogenic shock within 24 hours 10 (1.7%) 8 (19.5%) p < 0.001 60.37 
Cardiac arrest within 24 hours 10 (1.7%) 4 (9.8%) p < 0.001 35.11 
Pre-PCI insertion of IABP or other 
mechanical ventricular support device 
16 (2.7%) 9 (22.0%) p < 0.001 61.04 
PCI Status: Elective 231 (39.6%) 6 (14.6%) p = 0.001 58.56 
PCI Status: Urgent 267 (45.8%) 20 (48.8%) p = 0.711 5.98 
PCI Status: Emergency 85 (14.6%) 11 (26.8%) p = 0.036 30.58 
PCI Status: Salvage 0 (0.0%) 4 (9.8%) p < 0.001 46.50 
Post procedural outcomes     
Cardiogenic Shock 58 (9.9%) 30 (73.2%) p < 0.001 167.30 
Heart Failure 36 (6.2%) 8 (19.5%) p = 0.001 40.72 
 
SD: Standard deviation, CAD: coronary artery disease, MI: myocardial infarction, PCI: percutaneous coronary intervention, 
CABG: coronary artery bypass grafting, STEMI: ST-segment elevation myocardial infarction, IABP: intra-aortic balloon pump, 
CK-MB: creatinine kinase, CVA: cerebral vascular accident 
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Figure 1. Risk adjusted mortality, transfusion and contrast-induced acute kidney injury (CI-AKI) 
rates for subgroups defined by gender and perforation   
 
1A. Risk adjusted mortality associated with coronary perforation in men and women   
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1B. Risk adjusted transfusion associated with coronary perforation in men and women   
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1C. Risk adjusted CI-AKI associated with coronary perforation in men and women   
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Figure 2: Long term mortality of patients with and without coronary artery perforation among 
those discharged alive after PCI.  
 
 
  
90 days 
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Supplementary Table 1: Covariates included in propensity matching of patients with and without 
coronary artery perforation 
 
PCI Indication: 
1) Immediate PCI for STEMI 
2) PCI for STEMI (Unstable) 
3) PCI for STEMI (Stable) 
4) PCI for STEMI, stable after successful full-dose 
Thrombolysis) 
5) Rescue PCI for STEMI (after failed full-dose 
lytics) 
6) PCI for high risk Non-STEMI or unstable 
angina 
7) Staged PCI 
8) Other 
CAD presentation: 
1) No symptom, no angina 
2) Symptom unlikely to be ischemic 
3) Stable angina 
4) Unstable angina 
5) Non-STEMI 
6) STEMI or equivalent 
PCI status: 
1) elective              2) urgent 
3) emergency         4) salvage 
Admission source: 
1) admitted from emergency department 
2) transfer 
3) other 
Smoking status (current smoker) Prior CABG 
Hypertension Height 
Dyslipidemia Weight 
Family history of CAD Currently on dialysis 
Prior MI Prior cerebrovascular disease 
Prior heart failure Prior peripheral artery disease 
Prior valve surgery Chronic lung disease 
Prior PCI Diabetes 
Heart failure within the past 2 weeks LV ejection fraction less than 40% 
Pre-procedural Hemoglobin Race (white, black, Asian, other – allowing 
selection of multiple categories) 
Cardiomyopathy and/or left ventricular 
dysfunction 
Prior cardiogenic shock (within 24 hours) 
Prior cardia  arrest (within 24 hours) Cardiogenic shock at start of PCI 
procedure 
Age Gender 
Predicted patient mortality risk based on BMC2 
mortality risk model. 
 
CAD: coronary artery disease, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary artery 
bypass grafting, NSTEMI: non-ST segment elevation myocardial infarction, STEMI: ST segment elevation myocardial 
infarction, BMC2: Blue Cross Blue Shield of Michigan Cardiovascular Consortium, LV: left ventricular
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Supplementary Table 2: Comparison of propensity matched cohorts of patients with and without 
coronary artery perforation 
 
Characteristic No Perforation Perforation p-value 
Absolute 
Standard 
Difference 
Age 74.74 ± 9.51 74.16 ± 10.75 p = 0.597 5.75 
Sex     
   Male 483/1,030 (46.9%) 50/103 (48.5%) p = 0.749 3.30 
   Female 547/1,030 (53.1%) 53/103 (51.5%) p = 0.749 3.30 
Height 166.37 ± 10.69 166.63 ± 11.26 p = 0.822 2.38 
Weight 80.45 ± 19.71 80.83 ± 20.16 p = 0.856 1.90 
Race     
   White 978/1,030 (95.0%) 98/103 (95.1%) p = 0.931 0.90 
   Black  32/1,030 (3.1%) 3/103 (2.9%) p = 0.913 1.14 
   Asian 8/1,030 (0.8%) 1/103 (1.0%) p = 0.832 2.09 
Admit Source     
   Emergency department 464/1,030 (45.0%) 45/103 (43.7%) p = 0.791 2.74 
  Transfer in from another acute care facility 239/1,030 (23.2%) 26/103 (25.2%) p = 0.641 4.76 
   Other 327/1,030 (31.7%) 32/103 (31.1%) p = 0.888 1.46 
Current/Recent Smoker  154/1,030 (15.0%) 15/103 (14.6%) p = 0.916 1.10 
Hypertension 925/1,030 (89.8%) 92/103 (89.3%) p = 0.877 1.59 
Dyslipidemia 862/1,030 (83.7%) 86/103 (83.5%) p = 0.960 0.52 
Family History of Premature CAD 197/1,030 (19.1%) 19/103 (18.4%) p = 0.867 1.74 
Prior MI 406/1,030 (39.4%) 42/103 (40.8%) p = 0.788 2.77 
Prior Heart Failure 214/1,030 (20.8%) 22/103 (21.4%) p = 0.890 1.43 
Prior PCI 447/1,030 (43.4%) 46/103 (44.7%) p = 0.805 2.54 
Prior CABG 259/1,030 (25.1%) 27/103 (26.2%) p = 0.812 2.44 
Cerebrovascular Disease 258/1,030 (25.0%) 25/103 (24.3%) p = 0.862 1.80 
Peripheral Arterial Disease 282/1,030 (27.4%) 29/103 (28.2%) p = 0.866 1.73 
Chronic Lung Disease 210/1,030 (20.4%) 21/103 (20.4%) p = 1.000 0 
Diabetes Mellitus 440/1,030 (42.7%) 44/103 (42.7%) p = 1.000 0 
CAD Presentation     
   No angina 24/1,030 (2.3%) 2/103 (1.9%) p = 0.802 2.69 
   Symptom unlikely to be ischemic 18/1,030 (1.7%) 2/103 (1.9%) p = 0.886 1.44 
   Stable angina 95/1,030 (9.2%) 10/103 (9.7%) p = 0.871 1.66 
   Unstable angina 434/1,030 (42.1%) 43/103 (41.7%) p = 0.939 0.79 
   NSTEMI 254/1,030 (24.7%) 26/103 (25.2%) p = 0.896 1.35 
   STEMI  205/1,030 (19.9%) 20/103 (19.4%) p = 0.906 1.22 
PCI Status     
   Elective 350/1,030 (34.0%) 36/103 (35.0%) p = 0.843 2.04 
   Urgent 481/1,030 (46.7%) 48/103 (46.6%) p = 0.985 0.19 
   Emergency 199/1,030 (19.3%) 19/103 (18.4%) p = 0.830 2.23 
PCI Indication     
   Immediate PCI for STEMI 156/1,030 (15.1%) 16/103 (15.5%) p = 0.917 1.08 
   PCI for STEMI (Unstable, >12 hours from symptom onset) 49/1,030 (4.8%) 4/103 (3.9%) p = 0.689 4.30 
   PCI for high risk NSTEMI or unstable angina 581/1,030 (56.4%) 59/103 (57.3%) p = 0.865 1.76 
   Staged PCI 9/1,030 (0.9%) 1/103 (1.0%) p = 0.920 1.02 
   Other 235/1,030 (22.8%) 23/103 (22.3%) p = 0.911 1.16 
Heart Failure within two weeks  193/1,030 (18.7%) 19/103 (18.4%) p = 0.942 0.75 
Cardiomyopathy or left ventricular systolic dysfunction 124/1,030 (12.0%) 13/103 (12.6%) p = 0.863 1.77 
Cardiogenic Shock at start of PCI 50/1,030 (4.9%) 5/103 (4.9%) p = 1.000 0 
Pre-Procedure Hemoglobin 12.73 ± 1.80 12.73 ± 1.71 p = 0.975 0.32 
CAD: coronary artery disease, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, NSTEMI: 
non-ST segment elevation myocardial infarction, STEMI: ST segment elevation myocardial infarction,  
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Supplementary Table 3: Baseline mean predicted risks, outcomes, and adjusted odds ratios of 
patients with and without coronary artery perforation 
OR=odds ratio, CI-AKI=contrast-induced acute kidney injury, CI=confidence interval, O/E = 
observed/expected
 
Estimated baseline risk  
of death 
Estimated baseline 
risk  of CI-AKI 
Estimated baseline 
risk of transfusion 
No Perforation 1.51% 2.70% 2.94% 
Perforation 2.54% 3.28% 4.09% 
p-value p = .001 p = .026 p < .001 
    
 Mortality CI-AKI incidence 
Transfusion 
incidence 
No Perforation 1.50% 2.68% 2.91% 
Perforation 6.56% 7.95% 12.64% 
    
Overall rate: 1.52% 2.70% 2.95% 
    
O/E ratio: Death CI-AKI Transfusion 
No Perforation 0.99 0.99 0.99 
Perforation 2.58 2.42 3.09 
Adjusted OR 
5.00 (95% CI  3.42 – 
7.31) 
3.25 95% CI 2.30 – 
4.58) 
5.26 (95% CI 4.03-
6.87) 
p-value: p < .001 p < .001 p < .001 
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Supplementary Figure 1:  Overall incidence of CAP, proportion of PCI performed for treatment 
of CTO and incidence of CAP among CTO cases over a 5 year period                                                                                                  
Supplementary Figure 1A: Perforation rate by year 
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Supplementary Figure 1B: Treated CTO lesion rate by year 
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Supplementary Figure 1C: Perforation rate by year in patients with a treated CTO lesion 
 
  
CAP: coronary artery perforations, PCI: percutaneous coronary interventions, CTO: chronic total 
occlusions  
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